Sustained symptom relief in patients with psoriatic arthritis: Achievement of the stringent ACR50 endpoint was sustained at three years by 53.2% and 55.2% of patients with psoriatic arthritis (PsA) naïve to biologics or who had an inadequate response to, or were intolerant of, tumor...
Hence then, the article about bimzelx bimekizumab bkzx three year data at eular 2025 showed lasting efficacy and control of inflammation in psoriatic arthritis and axial spondyloarthritis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis )
Also on site :
- Feds announce 15 arrests in alleged $1.4 million public benefits fraud crackdown
- Taking an omega-3 supplement may not boost memory or cognition
- Julia Fox’s Video of Her Son Trying To Give Donuts to the NYPD at the Knicks Parade Will Make Your Day